PHV-wordings
Here you will find safety-relevant information that must be implemented in the corresponding product information due to a PHV (pharmacovigilance) issues.
Due to the relaunch of the EMA website in December 2023, you will find the current links to the entries prior to December 01, 2023 at https://www.ema.europa.eu
Levothyroxine
Additional template
|
02/12/2022
Further information is available in the CMDh press release (Report from the meeting held on 11-13 October 2022) on the HMA-Website.
Levothyroxine
PSUR-outcome
|
02/12/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Mesterolone
PSUR-outcome
|
01/12/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Gabapentin
PSUR-outcome
|
01/12/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Carboplatin
PSUR-outcome
|
01/12/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Mesalazine
PSUR-outcome
|
01/12/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Ketoprofen topical use only
PSUR-outcome
|
01/12/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
Riluzole
PSUR-outcome
|
25/11/2022
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Dorzolamide
Additional template
|
22/11/2022
Further information is available in the CMDh press release (Report from the meeting held on 11-13 October 2022) on the HMA-Website.
Dorzolamide
PSUR-outcome
|
22/11/2022
Further information and amendments to the product information in all EU languages are available on the EMA website.
